COVID-19 & Stem Cells treatment in Ukraine
Ensure the healthy future
People around the world have faced SARS-COV-19 pandemic, which causes COVID-19.
There is no antiviral therapy, and vaccine has not been developed yet. Studies show that even patients, who were asymptomatic, have changes in lungs.
causes a “cytokine storm” – a massive release of cytokines – cell hormones that destroy their own tissues, cause edema. Reduce protective functions due to a rapid decline in lymphocytes, cells that fight the virus.
causes pneumonia, due to the destruction of lung tissue leads to acute distress syndrome, respiratory failure.
increases inflammatory processes, leads to exacerbation of chronic diseases, especially dangerous for people with cardiovascular, respiratory diseases, impaired liver function and metabolism, immunosuppression, oncology.
Ukrainian experts developed a program to stabilize the immune system and restore patients who suffered from COVID-19. These are probably the world’s first reconstructive treatment protocols for people after COVID-19. They are based on many years of scientific and practical experience. Clinical trials conducted. The effectiveness of treatment is shown. Great achievement!
Biomedical visualization studio Visual Science has created the most detailed and scientifically accurate 3D model of the SARS-CoV-2 virus at atomic resolution. The model is based on the latest scientific research into the structure of coronaviruses, as well as input from expert virologists involved in the research. This is the most accurate model of the SARS-CoV-2 viral particle currently available. To produce it, Visual Science employed the same techniques of structural bioinformatics used in basic research and drug development.
The SARS-CoV-2 virus model is a part of Visual Science’s non-commercial Viral Park project. Viral Park’s past successes include models of HIV, influenza A/H1N1, Ebola, papilloma, and Zika virions.
We use the same color scheme throughout the whole Viral Park project. Bright colors show the proteins encoded by the viral genome. Shades of gray correspond to the structures taken by virus from the host cell. Thus we emphasize the parasitic and non-autonomous nature of the viruses.
Models and visualizations created for the Viral Park have received prizes from Science magazine and the National Science Foundation, and have been featured in leading media outlets such as Science, Nature Medicine, The New York Times, The Washington Post, Scientific American, Wired UK, Der Spiegel, Stern, National Geographic, GEO, and more.
FORBES about COVID-19 & Stem Cells treatment
“Melbourne-based biotech company Mesoblast announced earlier this week that it’s begun enrolling up to 300 patients for a randomized, controlled study of its stem cell therapy remestemcel-L in the treatment of COVID-19 patients experiencing acute respiratory distress syndrome. Over 20 hospitals will participate in the study, which is anticipated to last 3-4 months.
The announcement came about a week after the company reported that treatment with remestemcel-L in a group of 12 COVID-19 patients with ARDS at Mt. Sinai hospital in New York had a survival rate of 83%. The purpose of the randomized, controlled clinical trial is to test that survival rate on a larger scale.
“We were very pleased with preliminary data demonstrating the cells seem to have benefitted some of these patients,” says CEO Silviu Itescu. “If the cells work in COVID-19 ARDS, we’re in a position to provide products to as many patients as possible.”
“COVID-19 is the word that certainly isn’t forgotten by everybody who lives in the first half of the twenty-first century. COVID-19, as a pandemic, has led many researchers from different biomedical fields to find solutions or treatments to manage the pandemic. However, no standard treatment for this disease has been discovered to date. Probably, preventing the severe acute respiratory infection form of COVID-19 as the most dangerous phase of this disease can be helpful for the treatment and reduction of the death rate. In this regard, mesenchymal stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach and several clinical trials have begun. Recently, MSCs according to their immunomodulatory and regenerative properties attract attention in clinical trials. After the intravenous transplantation of MSCs, a significant population of cells accumulates in the lung, which they alongside immunomodulatory effect could protect alveolar epithelial cells, reclaim the pulmonary microenvironment, prevent pulmonary fibrosis, and cure lung dysfunction. Given the uncertainties in this area, we reviewed reported clinical trials and hypotheses to provide useful information to researchers and those interested in stem cell therapy. In this study, we considered this new approach to improve patient’s immunological responses to COVID-19 using MSCs and discussed the aspects of this proposed treatment. However, currently, there are no approved MSC-based approaches for the prevention and/or treatment of COVID-19 patients but clinical trials ongoing».
Golchin A, Seyedjafari E, Ardeshirylajimi A. Mesenchymal Stem Cell Therapy for COVID-19: Present or Future [published online ahead of print, 2020 Apr 13]. Stem Cell Rev Rep. 2020;1‐7. doi:10.1007/s12015-020-09973-w